전체 논문 (39편 · 1/2)
-
Conversion surgery after pembrolizumab for initially unresectable MSI-H small bowel adenocarcinoma: a case report and brief analysis.
-
Impact of antibiotics on survival outcomes and risk of gastritis/colitis in advanced-stage melanoma patients receiving immune checkpoint inhibitor therapy.
-
Symptoms, symptom burden, and influencing factors in patients treated with Nivolumab.
-
The game changer in the cervical cancer therapeutic landscape: immunotherapy.
-
Pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction cancer: KEYNOTE-859 Q-TWiST analysis.
-
Evaluating oral nutritional support and the nutritional risk scores in ICI-treated metastatic solid tumours.
-
Friendly fire? A case of inadvertent reactivation and progression of chronic lymphocytic leukemia following the treatment of cutaneous squamous cell carcinoma with Cemiplimab - case report.
-
Cost-effectiveness of first-line immune checkpoint inhibitor therapies, alone or combined with targeted agents, for unresectable hepatocellular carcinoma in China: an economic evaluation using network meta-analysis.
-
Immune checkpoint inhibitors in proofreading-deficient CRC: from molecular basis to clinical practice and future directions.
-
The role of bronchoscopic cryoimmunotherapy in non-small cell lung cancer: current evidence and future perspectives.
-
First-line treatments for metastatic non-small-cell lung cancer with sugemalimab plus chemotherapy: a China-based cost-effectiveness analysis.
-
A case report of breast cancer recurrence with cystitis: the impact of immune checkpoint inhibitor therapy on the incidence of cystitis.
-
Combination of anti-PD-1 treatment with chemotherapy in a patient with metaplastic breast cancer during lactation.
-
Financial barriers to immunotherapy: challenges and potential mitigation strategies: a review paper.
-
MicroRNA prognostic markers for immune checkpoint inhibitor success in urologic cancers.
-
Neoadjuvant immune checkpoint inhibitors for muscle-invasive urothelial carcinoma: a systematic review and meta-analysis.
-
Efficacy of first-line immune checkpoint inhibitors for recurrent/metastatic head and neck cancer: a systematic review and meta-analysis.
-
Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab.
-
5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLC.
-
Effects of serotonergic drugs on immune checkpoint inhibitor response: a pooled analysis of individual patient data from four Canadian Cancer Trials Group (CCTG) trials.
-
Remarkable response to anti-PD-L1 blockade in relapsed and refractory metastatic malignant giant cell tumor of bone: a case report.
-
Tsunami of approvals for immune checkpoint inhibitors in early setting of head and neck tumors.
-
Addressing social and economic disparities in triple-negative breast cancer immunotherapy: a U.S.-focused review.
-
Multisystem immune-related adverse events during combined ipilimumab-nivolumab with subsequent disease progression: a case report.
-
Immunotherapy expectations and knowledge in practice and clinical trials: a cross-sectional study.
-
Multi-omics insights into gut microbial dysbiosis and metabolic alterations in immune checkpoint inhibitor-induced thrombocytopenia.
-
Stereotactic body radiation therapy plus adoptive vNKT cell therapy for pancreatic cancer: protocol of a phase II trial.
-
Exploring the role of immunotherapy in the management of follicular cell-derived thyroid cancer.
-
Extended survival of a patient with gastrointestinal multiple malignancies managed with anti-PD-1 immunotherapy: a case report.
-
Effect of infection on immunotherapy for gastrointestinal cancer: a narrative review.